Evaluation of PRG4 mRNA-loaded polymeric nanoparticles in vitro and in vivo models of osteoarthritis
European Journal of Pharmaceutical Sciences · 2026-12 · 227 · 107690
DOI: 10.1016/j.ejps.2026.107690 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2026-12. Verfasst von Katrin Agnes Muenzebrock und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Proteoglycans, RNA, Messenger, Nanoparticles, Osteoarthritis. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, Dutch Research Council.
Abstract (Originalsprache)
BACKGROUND: Osteoarthritis (OA) is a highly prevalent degenerative joint disease for which no disease-modifying treatments are available. Proteoglycan 4 (PRG4) is a glycoprotein with lubricating and immunomodulatory properties, making it a promising therapeutic target for mRNA-based therapies. Therefore, this study evaluated the effects of PRG4 mRNA delivered via polymeric nanoparticles in both in vitro and in vivo OA models. METHODS: Human chondrocytes from OA patients were cultured in 3D pellet models and transfected with PRG4 mRNA-loaded polymeric nanoparticles at low or high dose, once or twice, respectively. Viability, pellet growth, glycosaminoglycan (GAG) production and mRNA expression were assessed, with EGFP mRNA transfection as a negative control. In vivo, an osteoarthritis rat model was used to evaluate PRG4 mRNA effects on pain behavior, cartilage degeneration, and synovial inflammation. RESULTS: In vitro, nanoparticle treatment induced an increase in pellet size and overall GAG production, independent of their cargo. PRG4 mRNA nanoparticle treatment at lower doses increased total pellet GAG content and early GAG release. Higher doses showed no additional benefit, and repeated transfection of the high dose significantly decreased cell viability. Double transfection of either dose showed increased relative expression of PRG4 mRNA, indicating uptake of the nanoparticles into the pellet. In vivo, PRG4 mRNA nanoparticles did not alleviate pain, reduce OA severity, or mitigate synovial inflammation. Sham-operated joints injected with mRNA-loaded nanoparticles showed increased OA and inflammation scores compared to healthy joints. CONCLUSIONS: MRNA-loaded nanoparticles increased extracellular matrix production in vitro independent of mRNA sequence. A minor effect of delivering PRG4 mRNA compared to control mRNA was found in matrix production normalized to cell content, but this was not reproduced in vivo. An intrinsic effect of nanoparticles on matrix production is suggested. Further research into the biodistribution of the presented nanoparticles and their cellular uptake into the different joint tissues is necessary for the advancement of mRNA-based treatments of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, University Medical Center Utrecht, Utrecht, the Netherlands.
- 20Med Therapeutics BV, Leiden, the Netherlands.
- Center for Translational Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Orthopedics, Diakonessenhuis Hospital, Utrecht, the Netherlands.
- Department of Orthopedics, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: laura.creemers@maastrichtuniversity.nl.
- Department of Orthopedics, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: J.L.Rios-2@umcutrecht.nl.
Förderung
- Horizon 2020
- Dutch Research Council
Zitieren
APA
Muenzebrock, K. A., Warmink, K., Escudero Franch, R., Koster, D. M. J., Rijker, M., Dilek, Y., Du, J., Pontes, A. P., Eijkelkamp, N., Bekkers, J., Rip, J., Creemers, L. B., & Rios, J. L. (2026). Evaluation of PRG4 mRNA-loaded polymeric nanoparticles in vitro and in vivo models of osteoarthritis. European Journal of Pharmaceutical Sciences, 227, 107690. https://doi.org/10.1016/j.ejps.2026.107690
Vancouver
Muenzebrock KA, Warmink K, Escudero Franch R, Koster DMJ, Rijker M, Dilek Y, et al. Evaluation of PRG4 mRNA-loaded polymeric nanoparticles in vitro and in vivo models of osteoarthritis. European Journal of Pharmaceutical Sciences. 2026;227:107690. doi:10.1016/j.ejps.2026.107690
BibTeX
@article{Muenzebrock2026,
author = {Muenzebrock, Katrin Agnes and Warmink, Kelly and Escudero Franch, Remei and Koster, Daniela M J and Rijker, Mattie and Dilek, Yeter and Du, Jie and Pontes, Adriano P and Eijkelkamp, Niels and Bekkers, Joris and Rip, Jaap and Creemers, Laura B and Rios, Jaqueline Lourdes},
title = {Evaluation of PRG4 mRNA-loaded polymeric nanoparticles in vitro and in vivo models of osteoarthritis},
journal = {European Journal of Pharmaceutical Sciences},
year = {2026},
volume = {227},
pages = {107690},
doi = {10.1016/j.ejps.2026.107690}
}
EUVIMED